Course: Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
CME Credits: 1.00
Released: 2021-04-05
In December 2020, 2 mRNA-based COVID-19 vaccines (Pfizer-BioNTech and Moderna) were granted Emergency Use Authorization by the US Food and Drug Administration as 2-dose series and recommended for use by the Advisory Committee on Immunization Practices.- In late February 2021, the US Food and Drug Administration granted Emergency Use Authorization for a third COVID-19 vaccine, a single-dose adenovirus vector-based vaccine from Janssen (Johnson & Johnson).
Educational Objective
To identify the key insights or developments described in this article
View Full Course